BS_C6SKJG3N
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 114.09329829172141
- age_years
- 5.268
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.526
- INFLAMMATORY_RESPONSE+0.525
- ALLOGRAFT_REJECTION+0.519
- INTERFERON_GAMMA_RESPONSE+0.498
- TNFA_SIGNALING_VIA_NFKB+0.494
- INTERFERON_ALPHA_RESPONSE+0.443
- COAGULATION+0.411
- IL2_STAT5_SIGNALING+0.403
- COMPLEMENT+0.398
- BILE_ACID_METABOLISM+0.361
Top 10 suppressed
- E2F_TARGETS-0.564
- G2M_CHECKPOINT-0.514
- MYC_TARGETS_V1-0.487
- DNA_REPAIR-0.478
- OXIDATIVE_PHOSPHORYLATION-0.470
- MYC_TARGETS_V2-0.463
- MITOTIC_SPINDLE-0.232
- UNFOLDED_PROTEIN_RESPONSE-0.230
- GLYCOLYSIS-0.169
- SPERMATOGENESIS-0.132
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_5NWDARXG | pilocytic astrocytoma | — | 0.970 |
| 2 | BS_AP0SZ364 | low-grade glioma | — | 0.968 |
| 3 | BS_Z7Y2466H | pilocytic astrocytoma | — | 0.951 |
| 4 | BS_401R3KV0 | pilocytic astrocytoma | — | 0.951 |
| 5 | BS_52426AMF | low-grade glioma | — | 0.942 |
| 6 | BS_6P50QTPP | low-grade glioma | — | 0.932 |
| 7 | BS_E4GC9EXR | Ganglioglioma | — | 0.929 |
| 8 | BS_8VAZSJEN | pilocytic astrocytoma | — | 0.929 |
| 9 | BS_KXH37MPN | DNET | — | 0.929 |
| 10 | TCGA-38-4626-01A-01R-1206-07 | — | cohortMD2 | 0.928 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.526 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.525 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.519 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.498 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.494 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.443 | Inavolisib | — uncovered |
| COAGULATION | 0.411 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.403 | Idelalisib | — uncovered |
| COMPLEMENT | 0.398 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.361 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.361 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.359 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.346 | Inavolisib | — uncovered |
| APOPTOSIS | 0.287 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.280 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.276 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.237 | Inavolisib | — uncovered |